Executive Board
The Executive Board has been established to assist the Chief Executive in leading The Institute of Cancer Research to achieve its strategic aims and objectives within the approved strategies and budgets and is responsible for formulating strategies, plans and budgets for approval by the Board of Trustees.
Professor Kristian Helin
Chief Executive and President
Professor Kevin Harrington
Head of Division – Radiotherapy and Imaging
Professor Clare Isacke
Dean of Academic and Research Affairs
Paul Norris
Chief Financial Officer
Jonathan Monk
Chief Information Officer
Professor Jonathon Pines
Head of Division – Cell and Molecular Biology
Dr Barbara Pittam
Chief Research and Academic Officer
Dr Olivia Rossanese
Head of Division – Cancer Therapeutics
Latest ICR News
New computational breakthrough helps uncover how water molecules influence cancer drug potency
In a major step forward for cancer drug discovery, researchers have demonstrated how computational simulations can unravel the complex role of water molecules in drug binding, potentially saving years of trial and error in the lab.
.jpg?sfvrsn=83f9c0d2_1 "human-cells-with-acute-myelocytic-leukemia-(aml)")
Why men fare worse in acute myeloid leukaemia: new study rules out hormone signalling
New research has ruled out hormone signalling as the reason why men with acute myeloid leukaemia (AML) tend to have poorer outcomes than women, even when treated with the same intensive chemotherapy – a finding that helps refine future research and could influence clinical trial design.
Embracing mathematics is key to illuminating cancer cell evolution
A new review explains how turning to mathematics is helping researchers decode one of cancer’s most elusive traits: its ability to evolve and adapt.
New combination treatment could overcome immunotherapy resistance in difficult-to-treat cancers
A pioneering clinical trial has demonstrated for the first time that two existing treatments can be combined to potentially improve outcomes for sarcoma and melanoma patients with advanced tumours in their limbs.